Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Agilent Technologies; Dionex; UCSF

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies this week said that it had completed the acquisition of certain assets of A2 Technologies for an undisclosed sum. Agilent inked the agreement last month to acquire specific assets of A2 Technologies, a Danbury, Conn.-based developer of Fourier transform infrared technology for lab and field use.

Dionex this week reported that its second-quarter revenues increased around 14 percent to $124.1 million from $109.2 million year over year. The firm's net income was $18.9 million, or $1.04 per share, compared to $16.9 million, or $.92 per share, for the second quarter of the previous year.

The chromatography systems maker signed a deal in December to be acquired by Thermo Fisher Scientific for approximately $2.1 billion.

The University of California, San Francisco, this week opened its $123 million Ray and Dagmar Dolby Regeneration Medicine Building. The new facility houses the Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research at UCSF. No federal funds were used in constructing the facility or purchasing equipment for it, meaning the research conducted there is immune to variations in federal funding policy regarding human embryonic stem cell research, UCSF said in a statement.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.